{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:23:34Z","timestamp":1787027014573,"version":"build-2736575974"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T00:00:00Z","timestamp":1611100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    CKLF-like MARVEL transmembrane domain-containing 6 (CMTM6) reportedly stabilizes programmed death-ligand 1 (PD-L1) and enhances the efficacy of immunotherapy. However, correlations between CMTM6 expression and the immune microenvironment and its prognostic value remain unknown in a variety of tumors.\n                    <jats:italic>CMTM6<\/jats:italic>\n                    expression data were obtained from The Cancer Genome Atlas (TCGA) for 33 cancer types classified into high and low expression subgroups according to the median CMTM6 expression value. Pan-cancer analysis of CMTM6 protein expression in 20 tumor types was performed using a cohort from the Human Protein Atlas (HPA). PD-L1 protein expression data were obtained from The Cancer Proteome Atlas (TCPA) for 32 cancer types. Frequencies of CMTM6 copy number alterations and mutations were analyzed using cBioPortal. MANTIS was employed to estimate microsatellite instability in the TCGA cohort. CIBERSORT and the ESTIMATE algorithm were applied to estimate the relative fractions of infiltrating immune cell types and immune scores, respectively. Kaplan\u2013Meier survival curve analysis was performed to assess the pan-cancer prognostic value of\n                    <jats:italic>CMTM6<\/jats:italic>\n                    .CMTM6 is heterogeneously expressed in diverse cancers. Further, the results revealed low\n                    <jats:italic>CMTM6<\/jats:italic>\n                    mutation frequencies in multiple cancers. Among them,\n                    <jats:italic>CMTM6<\/jats:italic>\n                    mutation frequency was the highest in uterine cancer. Additionally, CMTM6 expression was related to PD-L1 protein expression in breast invasive carcinoma, cervical squamous cell carcinoma and endocervical adenocarcinoma, cholangiocarcinoma, glioblastoma multiforme (GBM), head and neck squamous cell carcinoma, kidney renal papillary cell carcinoma, sarcoma (SARC), stomach adenocarcinoma, and uterine carcinosarcoma. Increased CMTM6 expression may be associated with increased infiltration of neutrophils in some types of cancer. Finally, pan-cancer analysis indicated that CMTM6 expression was closely related to overall survival in adrenocortical carcinoma, GBM, acute myeloid leukemia, liver hepatocellular carcinoma, mesothelioma, SARC, thymoma, and uveal melanoma. Taken together, these findings highlight that CMTM6 plays an important role in the tumor immune microenvironment, and CMTM6 has been identified to have prognostic value in some types of cancers. Thus, CMTM6 is a potential target for cancer immunotherapy and effective prognostic biomarker.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2020.585961","type":"journal-article","created":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T02:04:48Z","timestamp":1611108288000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":41,"title":["Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment"],"prefix":"10.3389","volume":"10","author":[{"given":"Yanbin","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihong","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyue","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,1,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s0888-7543(03)00095-8","article-title":"Identification of eight genes encoding chemokine-like factor superfamily members 1-8 (CKLFSF1-8) by in silico cloning and experimental validation","volume":"81","author":"Han","year":"2003","journal-title":"Genomics"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2018.08.012","article-title":"CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas","volume":"35","author":"Guan","year":"2018","journal-title":"EBioMedicine"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.09.014","article-title":"Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer","volume":"14","author":"Zugazagoitia","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00339","article-title":"Progress and Challenges in Precise Treatment of Tumors With PD-1\/PD-L1 Blockade","volume":"11","author":"Jiang","year":"2020","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e1920833","DOI":"10.1001\/jamanetworkopen.2019.20833","article-title":"Assessment of Clinical Activity of PD-1 Checkpoint Inhibitor Combination Therapies Reported in Clinical Trials","volume":"3","author":"Schmidt","year":"2020","journal-title":"JAMA Netw Open"},{"key":"B6","doi-asserted-by":"publisher","first-page":"556","DOI":"10.3390\/ijms21020556","article-title":"Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection","volume":"21","author":"Iivanainen","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nature23643","article-title":"CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity","volume":"549","author":"Burr","year":"2017","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nature23669","article-title":"Identification of CMTM6 and CMTM4 as PD-L1 protein regulators","volume":"549","author":"Mezzadra","year":"2017","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.21037\/atm.2017.11.26","article-title":"CMTM6 stabilizes PD-L1 expression and refines its prognostic value in tumors","volume":"6","author":"Mamessier","year":"2018","journal-title":"Ann Transl Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106864","article-title":"CMTM6 is positively correlated with PD-L1 expression and immune cells infiltration in lung squamous carcinoma","volume":"88","author":"Shang","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discovery"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2514","article-title":"Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples","volume":"31","author":"Cibulskis","year":"2013","journal-title":"Nat Biotechnol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/po.17.00073","article-title":"Landscape of Microsatellite Instability Across 39 Cancer Types","volume":"2017","author":"Bonneville","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat Commun"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"B17","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3390\/cancers12030738","article-title":"Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2019.1629261","article-title":"Increased CMTM6 can predict the clinical response to PD-1 inhibitors in non-small cell lung cancer patients","volume":"8","author":"Koh","year":"2019","journal-title":"Oncoimmunology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.67.2477","article-title":"Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma","volume":"34","author":"Daud","year":"2016","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)32517-x","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.critrevonc.2016.03.007","article-title":"Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1\/PD-L1 agents: A meta-analysis","volume":"101","author":"Abdel-Rahman","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and Function of the PD-L1 Checkpoint","volume":"48","author":"Sun","year":"2018","journal-title":"Immunity"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor Mutational Burden and Response Rate to PD-1 Inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-019-0738-1","article-title":"Mismatch repair deficiency\/microsatellite instability-high as a predictor for anti-PD-1\/PD-L1 immunotherapy efficacy","volume":"12","author":"Zhao","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.10.002","article-title":"Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAF(v600) mutation-positive melanoma receiving adjuvant vemurafenib","volume":"31","author":"Ascierto","year":"2020","journal-title":"Ann Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12943-019-1117-9","article-title":"The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications","volume":"18","author":"Liu","year":"2019","journal-title":"Mol Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41423-018-0027-x","article-title":"Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer","volume":"16","author":"Wang","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.52","article-title":"Neutrophils in cancer: neutral no more","volume":"16","author":"Coffelt","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B34","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-020-02741-2","article-title":"OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1\/2 signaling pathway","volume-title":"Cancer Immunol Immunother","author":"Pang","year":"2020"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1089\/dna.2018.4513","article-title":"Expression and Clinical Significance of CMTM6 in Hepatocellular Carcinoma","volume":"38","author":"Zhu","year":"2019","journal-title":"DNA Cell Biol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106478","article-title":"Molecular and immune characteristics for lung adenocarcinoma patients with CMTM6 overexpression","volume":"83","author":"Wang","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B37","doi-asserted-by":"crossref","DOI":"10.21203\/rs.3.rs-38154\/v1","article-title":"Prognostic implications of pan-cancer CMTM6 expression and its relationship with the immune microenvironment","volume-title":"ResearchSquare","author":"Zhang","year":"2020"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.585961\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T01:54:35Z","timestamp":1618883675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.585961\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,20]]},"references-count":37,"alternative-id":["10.3389\/fonc.2020.585961"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.585961","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,20]]},"article-number":"585961"}}